Doctolib: Health-Tech and the SaaS Model

Millions of Europeans now book their doctor’s appointment through a single app — Doctolib — which turned the humdrum task of medical scheduling into one of the continent’s most valuable health-tech companies. By selling subscription software to doctors and connecting them to patients, it built a dominant, recurring-revenue business. This article explains the software-as-a-service model, why dominance in a network business is so powerful, and the scrutiny it brings.

What is Doctolib and what does it do?

Doctolib is a French health-technology company that operates the leading online platform for booking medical appointments and managing healthcare practices. For patients, it is an app and website to find doctors and book appointments easily; for healthcare professionals — doctors, dentists, clinics, hospitals — it is software to manage their calendars, appointments, patient records, teleconsultations and administrative work.

Founded in 2013 by Stanislas Niox-Château, Doctolib has grown into one of Europe’s largest and most valuable health-tech companies, valued at over $6 billion, operating in France, Germany and Italy. In France it has become the dominant platform, used by a huge share of doctors and handling the overwhelming majority of online medical appointment bookings — it has become almost synonymous with booking a doctor’s appointment.

Doctolib earns its revenue not from patients (who use it free) but from the healthcare professionals who pay a subscription to use its software. This subscription, software-as-a-service model is central to understanding the company’s success and its high value. By reaching around $400 million in annual subscription revenue while sharply reducing its losses, Doctolib has shown its model can be both large and, increasingly, profitable — a milestone for a European tech champion in the France Company Stories hub.

What is the software-as-a-service (SaaS) model?

Software-as-a-service (SaaS) — Doctolib’s business model — means providing software to customers over the internet in exchange for a recurring subscription fee (typically monthly), rather than selling it once. Doctors and clinics pay Doctolib a regular subscription to use its booking and practice-management software, and in return get continually updated, cloud-based tools they access online.

SaaS is prized because it generates recurring, predictable revenue. Instead of earning a one-off payment, Doctolib earns a steady monthly fee from each of its many healthcare-professional customers, month after month, year after year — revenue that recurs automatically as long as they remain subscribed. Because switching software is disruptive for a busy medical practice (retraining staff, migrating data, changing patient habits), customers tend to stay, giving Doctolib a sticky, dependable revenue base.

This model is also highly scalable and profitable once established: after the software is built, serving each additional customer costs relatively little, so revenue flows through richly as the customer base grows. The combination of recurring, sticky revenue and scalable economics is why SaaS companies are among the most valued in technology, and why Doctolib — a SaaS business embedded in the essential, enormous healthcare market — commands such a high valuation. It is the same recurring-revenue logic that makes software companies like Dassault Systèmes so valuable, applied to healthcare.

Why is dominance in a network business so powerful?

Doctolib’s dominance in France — handling over 90% of online medical bookings — is so powerful because it is a network business, where value grows as more people use it, creating a self-reinforcing advantage that is very hard for rivals to challenge. The more doctors use Doctolib, the more useful it becomes to patients (who can find and book almost any doctor there), and the more patients use it, the more essential it becomes for doctors to be on it.

This ‘network effect’ creates a virtuous circle that entrenches the leader. Once Doctolib became the platform where both doctors and patients expected to be, joining it became almost mandatory for a doctor wanting to be found and for a patient wanting to book easily — and any competitor faced the near-impossible task of persuading both sides to switch to a platform that started with far fewer users. Dominance, once achieved, tends to reinforce itself.

The result is a powerful, defensible position: Doctolib became the default infrastructure for booking healthcare in France, an almost indispensable utility with a commanding market share and the pricing power and stability that come with it. Building such a category-defining, network-effect-driven platform is one of the most valuable achievements in technology — but, as Doctolib is discovering, dominance also attracts the attention of regulators, the flip side of winning a network business so completely.

What scrutiny does dominance bring?

Doctolib’s very success has brought it under the scrutiny of competition regulators, who worry that a company controlling over 90% of a market can abuse that dominance to harm competition and customers. France’s competition authority examined Doctolib’s practices and fined it for conduct — including exclusivity arrangements and its earlier acquisition of a leading rival — judged to entrench its dominant position unfairly.

This is the classic dilemma of a dominant platform: the network effects and market share that make it so successful and valuable also make it a target for regulators charged with protecting competition. Authorities may scrutinise how a dominant company treats rivals, whether it locks customers into exclusive deals, whether its acquisitions reduce competition, and whether its market power lets it raise prices or degrade choice. What looks like winning to the company can look like a competition problem to regulators.

For Doctolib, this scrutiny is a serious risk and a management challenge: it must navigate regulatory constraints, defend or adjust its practices, and manage its dominance responsibly, all while continuing to grow. The tension is inherent to its position — the more completely it wins its market, the more regulatory attention it invites. It is a challenge shared by dominant companies across the France Company Stories hub, from EssilorLuxottica in eyewear to Doctolib in health-tech: extraordinary success in a market is precisely what draws the regulators in.

How does Doctolib expand and diversify?

Having dominated online booking in France, Doctolib is expanding in two directions: geographically, into Germany and Italy, and functionally, by adding more services for healthcare professionals beyond simple appointment booking. This growth strategy aims to build on its strong position and increase the value it provides — and earns — from each customer.

Geographic expansion takes Doctolib’s proven model into large new markets, though it must rebuild its network effects country by country, competing against local rivals and adapting to different healthcare systems and regulations. Functional expansion — adding teleconsultation (video appointments), practice-management tools, patient-record systems, messaging and more — deepens Doctolib’s role in healthcare, making its software more essential and allowing it to charge more per customer.

This dual expansion is how a SaaS platform grows beyond its original niche: widening its geographic reach and deepening its product to become ever more embedded in its customers’ operations. By evolving from a booking tool into a broader operating system for healthcare practices, Doctolib aims to increase both its market and its indispensability — the path by which a category-defining platform sustains its growth once it has conquered its first market and use case.

What are the risks facing Doctolib?

Doctolib’s dominance brings regulatory risk — antitrust scrutiny, fines and constraints on its practices — that could limit how it operates and grows. It also handles highly sensitive medical data, so data privacy and security are critical: any breach or misuse would be gravely damaging to trust in a health platform. Expanding into new countries is hard, requiring it to rebuild networks and navigate different, often complex, healthcare systems.

It faces competition from other health-tech firms and potentially from large technology companies eyeing healthcare, and its high valuation demands continued strong growth to justify. Healthcare is also a heavily regulated, sometimes slow-moving sector, and Doctolib depends on the cooperation of healthcare professionals and systems. Balancing its drive to grow and monetise with the trust, privacy and regulatory expectations of a health platform is a continual challenge central to its future.

What can founders learn from Doctolib?

Doctolib is an excellent case study in the power of the SaaS model and network effects. By selling recurring-subscription software into the vast, essential healthcare market, and by building a two-sided platform whose value grew as more doctors and patients joined, it created a dominant, sticky, high-value business — showing how recurring revenue and network effects can combine into a formidable competitive position.

It also illustrates both the rewards and the responsibilities of dominance: winning a network market so completely brings pricing power and stability, but also regulatory scrutiny and the duty to handle great power — and sensitive data — responsibly. For anyone studying the France Company Stories hub, Doctolib is the case study in SaaS and category-defining platforms — proof that software subscriptions in a huge, essential market, combined with network effects, can build one of the continent’s most valuable technology companies. Explore the AI, fintech and marketplace champions around it across the French Tech Startups pillar.

Frequently Asked Questions